Corstasis Therapeutics Inc. ( a late clinical-stage innovator of therapies that enhance options for the treatment of fluid ...

J&J’s Innovative Medicine business continued its solid growth in the second quarter of 2025 with sales rising 4.9% year over ...

Johnson & Johnson delivered a "beat and raise" quarter. Results were bolstered by the new acquisition of Intra-Cellular, ...

Some of the most high-profile acquisitions in recent years have involved women-fronted biotechs. BioSpace reviews five of the ...

ABBV's neuroscience sales are projected to jump 15% in Q2, driven by Botox Therapeutic, Vraylar and oral migraine drug gains.

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and ...

From J&J to BMS, New Jersey pharmaceutical companies continue to expand and transform through M&A, leadership shifts and ...

IL-1 is considered one of the key mediators involved in the pathogenesis of OA, causing inflammation, joint pain, and ...

Waters plans to combine with the Biosciences & Diagnostic Solutions business of BD (Becton, Dickinson & Co.), the companies said, in a $17.5 billion deal that would be the year’s largest within life ...

DelveInsight's Parkinson's Disease Pipeline report depicts a robust space with 130+ active players working to develop 150+ ...

We know that heat is the deadliest climate impact, killing more Americans each year than floods, hurricanes, and tornadoes combined. But the mental health impacts of heat are less well-known.

JNJ which has outperformed the S&P 500 and other large-cap healthcare peers in H1-2025, now faces a crucial test with Q2 results due to be announced on ...